← Back

Outset Medical Inc

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Price · split & dividend adjusted
News & notes moving OM
OM▼

Outset Medical reports Q2 loss of $0.80 per share, revenue beats estimates

Outset Medical posted a second-quarter loss of $0.80 per share, missing the Zacks Consensus Estimate of a loss of $0.63 and marking an earnings surprise of negative 26.98%. Revenue came in at $31.64 million, surpassing the consensus estimate by 9.84% and edging above the year-ago figure of $31.42 million. The company has not beaten consensus EPS estimates in any of the last four quarters and has topped revenue estimates only once in that span. Shares have gained about 38% year-to-date, outpacing the S&P 500's 12.8% advance. The current consensus EPS estimate stands at a loss of $0.67 on $34.9 million in revenue for the coming quarter and a loss of $2.88 on $127.5 million in revenue for the full fiscal year.
OM ▼
Zacks Investment Research·20dRead more ▾
Biotech & Genomic Medicine▲

Can-Fite, SeaStar Medical, Elicio Lead Biotech Gainers on Study Updates and Revenue Growth

Can-Fite BioPharma, SeaStar Medical, and Elicio Therapeutics were among the top biotech gainers on Wednesday. Can-Fite soared over 55% after its Phase 2a pancreatic cancer study with Namodenoson met its primary safety endpoint and showed durable overall survival, prompting plans for a Phase 2b combination trial. SeaStar Medical jumped more than 30% as net revenue for its flagship QUELIMMUNE pediatric therapy rose to approximately $0.5 million in the first quarter of 2026 from $0.3 million a year earlier, with full-year 2026 product revenue expected to reach about $2 million. Elicio Therapeutics climbed over 31% following its addition to the Russell 2000 and Russell 3000 Indexes and the refinement of its Phase 3 development strategy for ELI-002, despite the Phase 2 AMPLIFY-7P trial missing its primary endpoint. Regentis Biomaterials gained more than 29% as it prepares to begin European surgeon training for its CE Mark-approved knee cartilage implant GelrinC. TransCode Therapeutics rose over 20% for a second straight day, with a Phase 2a trial of its metastatic cancer therapy TTX-MC138 underway and preliminary results expected in the fourth quarter of 2026. Outset Medical advanced over 18% after reporting first-quarter 2026 revenue of $27.9 million and projecting full-year revenue between $125 million and $130 million.
ELTX ▲ICU ▲OM ▲RNAZ ▲
Biotech & Genomic Medicine
RTTNews·56dRead more ▾
© 2026 MarketDXAsset